SEATTLE--(BUSINESS WIRE)--Phase Genomics, Inc., a leading innovator at the forefront of genomics technology development, today announced the appointment of David Shoultz, PhD, MBA as the company’s first Chief Business Officer. A strategic addition to the executive suite, Shoultz will drive growth as Phase Genomics accelerates market awareness and its work to amplify the impact of technological innovation at the frontiers of human health..

西雅图--（商业新闻短讯）--Phase Genomics，Inc.是基因组学技术发展前沿的领先创新者，今天宣布任命David Shoultz博士（MBA）为公司首任首席商务官。作为管理层的战略性补充，Shoultz将推动增长，因为Phase Genomics加速了市场意识及其扩大技术创新对人类健康前沿影响的工作。。

“David’s experience at leading organizations in diverse therapeutic areas and global public health is critical for Phase Genomics’ growth strategy,” said Ivan Liachko, PhD, founder and CEO of Phase Genomics. “He brings the right know-how at the right time to accelerate adoption for our suite of technologies that unlock and integrate new layers of scientific discovery.

Phase Genomics创始人兼首席执行官Ivan Liachko博士表示：“David在不同治疗领域和全球公共卫生领域领导组织的经验对于Phase Genomics的增长战略至关重要。”。“他在正确的时间带来了正确的专有技术，以加速采用我们的一套技术，从而解锁和整合科学发现的新层面。

We’re excited to have David aboard as we strengthen our mission to make the world a better, healthier place.”.

我们很高兴有大卫加入，因为我们加强了我们的使命，使世界成为一个更美好、更健康的地方。”。

Shoultz’s experience includes helping launch the Institute for Protein Design (IPD) spin-out Monod Bio, where he served as co-founder and COO prior to joining Phase Genomics. In addition to his role at Monod Bio, he was previously a key member of the global health product development team at the Bill & Melinda Gates Foundation before directing the global drug development program at PATH, and has also held scientific leadership positions at Neoleukin Therapeutics and PPD (acquired by Thermo Fisher Scientific).

Shoultz的经验包括帮助启动蛋白质设计研究所（IPD）spin out Monod Bio，在加入Phase Genomics之前，他曾担任联合创始人和首席运营官。除了在Monod Bio担任职务外，他之前是比尔和梅琳达·盖茨基金会全球健康产品开发团队的关键成员，然后在PATH指导全球药物开发计划，并在Neoleukin Therapeutics和PPD（由Thermo Fisher scientific收购）担任科学领导职务。

Shoultz has raised more than $150 million in venture and non-dilutive capital to accelerate ground-breaking innovations to the front lines of health and medicine..

Shoultz已经筹集了超过1.5亿美元的风险投资和非稀释性资本，以加速卫生和医学前沿的突破性创新。。

“Ivan and team built Phase Genomics on a relentless and infectious scientific curiosity. It’s one of the many reasons I am proud to join this team working at the frontiers of discovery. They’ve engineered incredible technological breakthroughs for nearly a decade, and there’s more on the way,” said David Shoultz, PhD, MBA, chief business officer at Phase Genomics.

Phase Genomics首席商务官、MBA博士大卫·舒尔茨（DavidShoultz）表示：“伊凡（Ivan）和他的团队建立在无情且具有感染力的科学好奇心之上。这是我加入这个团队在发现前沿工作的众多原因之一。他们在近十年来创造了令人难以置信的技术突破，还有更多突破。”。

“Phase Genomics has endeavored not only to advance leading-edge genomic tools for research, but to prove out their potential for real-world impact. Together, we’re meeting an enormous opportunity beyond the bench to alleviate the most tremendous needs across diverse therapeutic areas, including oncology and infectious disease.”.

“Phase Genomics不仅致力于推进前沿的基因组学研究工具，而且还致力于证明其对现实世界的影响潜力。我们共同创造了一个巨大的机会，可以缓解包括肿瘤学和传染病在内的各种治疗领域的最巨大需求。”。

In conjunction with his other professional roles, Shoultz currently holds an affiliate professorship in the University of Washington’s Department of Epidemiology and has served as a translational advisor within the University’s IPD. He has been an advisor to Phase Genomics since January 2024.

与其他专业角色一起，Shoultz目前在华盛顿大学流行病学系担任附属教授，并曾担任该大学IPD的翻译顾问。自2024年1月以来，他一直是Phase Genomics的顾问。

Shoultz will be attending the BIO Investor Forum this October 15-16, 2024, in San Francisco. Learn more by following Phase Genomics on X and LinkedIn for the latest news and information.

Shoultz将于2024年10月15-16日在旧金山参加生物投资者论坛。。

About Phase Genomics

关于相位基因组学

Phase Genomics applies proprietary ultra-long-range genome sequencing technology to enable genome assembly, microbiome discovery, as well as analysis of genomic integrity and chromosomal aberrations. In addition to a comprehensive portfolio of laboratory and computational services and products, including reagent kits and genomic services, they also offer an industry-leading genome and metagenome assembly and analysis software..

Phase Genomics应用专有的超长程基因组测序技术来实现基因组组装，微生物组发现以及基因组完整性和染色体畸变的分析。除了全面的实验室和计算服务和产品组合（包括试剂盒和基因组服务）外，他们还提供业界领先的基因组和宏基因组组装和分析软件。。

Based in Seattle, WA, the company was founded in 2015 by a team of genome scientists, software engineers, and entrepreneurs. The company’s mission is to empower scientists with genomic tools that accelerate breakthrough discoveries.

该公司成立于2015年，总部位于华盛顿州西雅图，由基因组科学家、软件工程师和企业家组成。该公司的使命是为科学家提供基因组工具，以加速突破性发现。